- 1
- 



**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

# **Abstract**

 Studies on artificial intelligence (AI) in screening for diabetic retinopathy (DR) have shown promising results in addressing the mismatch between the capacity to implement DR screening and the increasing DR incidence; however, most of these studies were done retrospectively. This review sought to evaluate the diagnostic test accuracy (DTA) of AI in screening for referable diabetic retinopathy (RDR) in real- world settings. We searched CENTRAL, PubMed, CINAHL, Scopus, and Web of Science on 9 February 2023. We included prospective DTA studies assessing AI against trained human graders (HGs) in screening for RDR in patients living with diabetes. synthesis Two reviewers independently extracted data and assessed methodological quality against QUADAS-2 criteria. We used the hierarchical summary receiver operating characteristics (HSROC) model to pool estimates of sensitivity and specificity and, forest plots and SROC plots to visually examine heterogeneity in accuracy estimates. Finally, we conducted sensitivity analyses to explore the effects of studies deemed to possibly affect the quality of the studies. We included 15 studies (17 datasets: 10 patient-level analysis (N=45,785), and 7 eye-level analysis (N=15,390). Meta-analyses revealed a pooled sensitivity of 95.33%(95% CI: 90.60-100%) and specificity of 92.01%(95% CI: 87.61-96.42%) for patient-level analysis; for the eye-level analysis, pooled sensitivity was 91.24% (95% CI: 79.15-100%) and specificity, 93.90% (95% CI: 90.63-97.16%). Subgroup analyses did not provide variations in the diagnostic accuracy of country classification and DR classification criteria; however, a moderate increase was observed in diagnostic accuracy at the primary-level and, a minimal decrease in the tertiary-level healthcare settings. Sensitivity analyses did not show any variations in studies that included diabetic macular edema in the RDR definition, nor in studies with ≥3 HGs. This review provides evidence, for the first time from prospective studies, for the effectiveness of AI in screening for RDR, in real-world settings.

# **Introduction**

 Diabetic retinopathy (DR) is the most common and specific complication of diabetes mellitus in the working age group [1]. In 2020, the number of adults with DR was estimated to be 103.12 million, which is expected to be 129.84 million by 2030 and 160.50 million by 2045 [1]. Along with an increasing incidence of DR, the number of people with vision impairment and blindness also increases. Without early intervention, the incidence of blindness due to DR will continue to rise as the number of people getting diabetes increases. Thus, DR has become a global public health concern, compelling researchers and health practitioners to continuously develop strategies to prevent and treat DR.

 Diabetic retinopathy can be asymptomatic for years, even at advanced stages [2]. Thus, early-stage detection of DR is crucial to provide timely treatment and management. For that reason, DR screening programmes are being implemented in public health settings through population-based or opportunistic screening. Diabetic retinopathy screening aims to distinguish between patients who need a referral, termed referable DR (RDR), for ophthalmological intervention from those who can continue annual routine eye care services [3]. Referable DR can be classified as moderate nonproliferative DR (NPDR) or worse and/or diabetic macular edema (DME). Those with RDR must be referred within three months to one year, depending on the resource settings [4].

 Currently, local and international programmes combatting DR are facing a significant crisis due to the increasing prevalence of diabetes. This influx has outpaced the development of healthcare services and screening programmes for preventing DR [5]. According to a systematic review by Piyasena et al. [6], aside from the high cost of services and lack of infrastructure for retinal imaging and training programmes, one of the major barriers to DR screening is the lack of skilled human resources, especially in the lower- and middle-income countries.

 Artificial intelligence has shown to be a promising solution to these challenges by functioning in an autonomous mode. Through deep learning algorithms, AI can be used to detect the presence and severity of DR in real-time. However, it is crucial that these tools should have high diagnostic accuracy and good performance before being implemented in various healthcare settings. The UK National Institute for Clinical Excellence (NICE) Guidelines stated that DR screening programmes should use screening

77 tools with a sensitivity of  $\geq 80\%$ , specificity of  $\geq 95\%$ , and a technical failure rate of  $\leq 5\%$  [7]. Meanwhile, the St Vicent Declaration of 2005 suggested that systematic DR screening programmes should aim for a sensitivity of ≥80% and a specificity of ≥90% with an acceptable coverage of ≥ 80% [8].

 In recent years, retrospective validation studies have shown AI to have high diagnostic accuracy in detecting DR; that is, AI is equally good or even better than human graders (HGs). Studies done in real-83 world settings using prospective data collection have also demonstrated robust performance [9]; however, these studies are fewer than those done in a retrospective manner, and the true utility of AI systems in DR screening will only be better understood through prospective studies, as performance is likely to be affected when dealing with real-world data that is different from the data used for algorithm 87 training [10, 11]. Moreover, prospective studies, with pre-established protocols, allow them to be more robust and generalisable, and exhibit the true impact on system usability in real-world settings.

 Therefore, we conducted a systematic review and meta-analysis of studies with prospective data collection in assessing the diagnostic accuracy of AI compared with trained HGs in screening for RDR in real-world settings. The findings of this review may offer evidence-based recommendations for integrating AI solutions to screen for RDR, especially in resource-challenged environments.

# **Methods**

## **Reporting, protocol, and registration**

 We drafted this review in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) guidelines [12]. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under CRD42023392297. An ethics waiver was granted by the University of Cape Town Human Research Ethics Committee.

## **Databases and search strategies**

 We searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE) via PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and Web of Science **(S1 Table)**. We also hand-searched the reference lists of relevant primary studies, systematic reviews, and the following journals: British Journal of Ophthalmology, American Journal of Ophthalmology, Ophthalmology and Retina, JAMA Ophthalmology, and Investigative Ophthalmology and Visual Science.

# **Eligibility criteria**

## **Type of studies**

We included randomised control trials (RCT) and observational analytical studies evaluating the DTA

of AI in DR screening. We excluded studies based on retrospective validation of existing images (i.e.,

medical records, available data sets). We excluded review articles, editorials, case series, case reports,

115 and qualitative studies.

## **Type of participants**

 We included participants with clinically diagnosed type 1 or type 2 diabetes with unknown DR status, regardless of age, sex, race/ethnicity, and geographical location. We excluded studies that enrolled participants with unconfirmed diabetes to avoid misclassifying participants, which may result in biased estimates of the association between diabetes and diabetic retinopathy.

**Setting**

 We only included studies conducted in real-world settings, thus excluding those done for theoretical algorithm training and validation alone.

## **Index test**

 We included interventions using AI for prospective screening of fundus images that could detect RDR or its equivalent.

## **Reference standard**

The reference standard was manual grading for DR by trained HGs who analysed the same fundus

images read by the AI. We excluded reference standards that did not use the same DR classification

criteria used by the AI during its software training to grade DR.

## **Target condition**

 We included studies that screened for RDR as defined by the authors of the primary studies. We included studies with RDR equivalence, i.e. more than mild DR, clinically significant DR, etc. We did not include patients or eyes with no RDR, and ungradable or inconclusive fundus images in the pooling of diagnostic accuracy outcomes. Including ungradable or inconclusive images may result in inaccuracy in assessing the AI system's performance, making it challenging to draw meaningful conclusions.

#### **Outcomes**

 We included studies reporting on, or containing the data necessary to extract information on the proportions of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). Efforts were made to contact corresponding authors to retrieve data which were unclear or unavailable 141 in the paper or supplementary materials.

## **Report characteristics**

We had no restrictions on the publication year and language. Study protocols were excluded.

- 
- 
- 
- 

## **Study selection**

 We used Rayyan software to manage the retrieved studies. Review authors (HU, CF) independently screened the titles and abstracts and classified them as (a) included, (b) maybe, and (c) excluded. Full- text articles of those 'included' and 'maybe' were obtained and independently assessed by the same authors against the eligibility criteria. Studies were then classified as (a) included, (b) excluded, and (c) awaiting authors' responses. Any disagreements were resolved between the two reviewers or by consulting a third review author (AH). We emailed the corresponding authors of studies included as 'awaiting authors' responses' at least three times with intervals of at least two weeks. If there were no responses from the authors, studies were classified under 'no author's response'.

# **Data extraction and management**

 We developed a data extraction form and divided it into two parts: (a) Study characteristics (relating to study designs, AI, and reference standards) and (b) Study outcomes: TP, FP, FN, TN**.** Two review authors extracted the study characteristics and study outcomes.

# **Risk of bias and acceptability**

 The risk of bias and applicability on the (a) patient selection, (b) index test, (c) reference standard, and (d) flow and timing of the included studies were independently assessed by two review authors (HU, CF) using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool [13]**.** We tailored, piloted, and refined our QUADAS-2 tool based on our review. Any disagreements were resolved between the two authors or by consulting a third review author (ME).

## **Data synthesis and analysis**

## **Quantitative data analysis and synthesis**

 We calculated each included study's sensitivity and specificity. We initially planned to analyse data only at the patient level; however, some studies reported only diagnostic accuracy on eye level (or image level), and some patient-level data cannot be extracted. Therefore, we considered looking into both of these levels for analysis. Heterogeneity was explored using visual inspection of forest plots and

 hierarchical summary receiver operating characteristics (HSROC) plots. All analyses performed and plots generated were done using Review Manager (RevMan) 5.4 and SAS® Studio.

#### **Subgroup analysis**

 We performed subgroup analyses on the following covariates identified a priori: level of economic development (World Bank country classification), level of the healthcare setting, and DR classification criteria. We did not include the modes of AI as previously planned since all AI modes of the included studies were automated.

#### **Sensitivity analysis**

 We initially planned to explore the effect of excluding studies with a high risk of bias. However, after excluding studies with a high risk of bias, all studies were left with an unclear risk. Nevertheless, we performed sensitivity analyses to investigate the exclusion of studies that did not include DME in the RDR definition; although we have stated that the definition of RDR will be according to how the authors of the primary studies defined it, many references still included DME as part of RDR definition, and the International Council of Ophthalmology (ICO) guidelines states that patients with DME should be 187 referred. We also investigated the exclusion of studies with  $\leq$  HGs as the ground truth for reference standard because this might incur bias if intergrader disagreements arise without having a third HG to arbitrate. According to Cardoso et al., ground truth means "data and/or method related to more consensus or reliable values/aspects that can be used as references" [14]. In our review, it refers to the final grading or assessment of fundus images by all HGs, which serves as the reference standard or the most reliable evaluation of the presence and severity of DR.

# **Results**

## **Results of the Search**

 We were able to identify a total of 3899 articles through searching of various databases. After deduplication, 2742 studies were screened by title/abstract, of which 2654 were excluded. The remaining 88 studies were screened for full-text assessment against the review's eligibility criteria. Of

 these, 70 studies were excluded, three were classified under 'no author's response', and finally, 15 were included for the quantitative synthesis **(Fig 1)**.

#### **Fig 1. PRISMA flow diagram of the study search and selection.**

## **Included studies**

 Please see **Tables 1a** and **1b** for the characteristics of included studies. Fifteen studies comprising 17 datasets were deemed eligible for this review, of which ten measured diagnostic accuracies at the patient level (45 785 patients) and seven at the eye level (15 390 eyes). We deemed all studies to be cross- sectional with prospective data collection; however, in our table of included studies, we presented the study designs according to how they were reported. Seven studies were done in China, five in India, and three in Australia. Seven studies were done at tertiary-level healthcare settings, six were done at the primary level, while the remaining two were done at both levels; no studies were done at the secondary level. For the target condition (RDR), six studies defined it as moderate NPDR or worse and/or DME, and nine did not include DME as part of the definition. Thirteen studies used ICDR or its equivalence as DR classification criteria, and two used the NHS DES criteria. For the reference standard, 12 studies have ≥3 HGs as the ground truth, and three studies have at most two HGs. Four studies developed their own AI models, and 11 used commercially available models. All studies used Inception with varying versions as their architecture. All AI software in the studies were fine-tuned with training data sets containing 25 297 to 207 228 fundus images. All studies used nonmydriatic cameras to capture fundus images, of which three still performed mydriasis on their patients using tropicamide eye drops, and one did mydriasis on a conditional protocol. Eight studies captured only one fundus field per eye (mostly macula-centred), and seven studies captured more than one fundus field. All studies 221 used a fundus camera with a narrow field of vision  $(45^{\circ} - 50^{\circ})$ .



#### **Table 1a. Key characteristics of the study design, population, target condition, and reference standard of included studies.**

" Study design according to study authors; b Sample included in the diagnostic accuracy analysis excluding ungradable images; "Samples were reported in image level, but the study captured one image per eye, so considered a <sup>d</sup> Study design not reported, thus deemed by review authors as cross-sectional based on the journals; <sup>e</sup> Mean was estimated from median using recommendations by Hong Kong Baptist University, Department of Mathematics [30 <sup>f</sup>Criteria was matched to the equivalent definition of RDR based on the ICDR classification.

COS, Chinese Ophthalmic Society; CSME, clinically significant macular edema; DME, diabetic macular edema; DR, diabetic retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study; HIC, high-income country; ICDR, International Clinical Diabetic Retinopathy; L-MIC, lower middle-income country; NHS DES, National Health Service Diabetic Eve Screening; NPDR, nonproliferative diabetic retinopathy; NR, not reported; RDR, referable diabet retinopathy; SD, standard deviation; T1D, Type 1 diabetes; T2D, Type 2 diabetes; U-MIC, upper middle-income country; WBC, World Bank classification; ZIRC, Zhongshan Image Reading Centre.

#### **Table 1b. Key characteristics of the index tests of included studies.**



**CARE,** Comprehensive AI Retinal Expert; **CNN**, convolutional neural network; **DNN**, deep neural network; **ILSVRC**, ImageNet Large Scale Visual Recognition Challenge; **NR**, not reported

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.06.20.23291687;](https://doi.org/10.1101/2023.06.20.23291687) this version posted June 22, 2023. The copyright holder for this preprint

## **Excluded studies**

- From the 88 full-text articles assessed for eligibility, we excluded 70 studies and classified three
- studies under 'no author's response'.

# **Methodological quality of included studies**

- A summary of methodological quality assessment is presented in **Figs 2** and **3**.
- **Fig 2. Risk of bias and applicability concerns summary: Review authors' judgments about each**
- **domain for each included study using the QUADAS-2 tool.**
- **Fig 3. Risk of bias and applicability concerns graph: Review authors' judgments about each**
- **domain presented as percentages across included studies using the QUADAS-2 tool.**
- 

## **Patient selection**

 In the patient selection domain, 12 of the 15 studies were deemed to have an unclear risk of bias in the sampling method. Most of the studies did not specify how patients were enrolled except for three studies (1 consecutive, 1 random, and 1 convenience sampling method). Two studies were not able to avoid inappropriate exclusions since one study excluded patients with macular edema, and the other study excluded those who were treated with ocular injections for DME or proliferative disease; of which these conditions are part of the definition of RDR, deeming these studies with a high risk of bias and high concern on applicability. For applicability on patient selection, 13 out of 15 studies have a low concern on applicability.

### **Index test**

244 In the domain of index tests, we added two signalling questions deemed necessary for index tests using AI, one of which is the quality of images fed into the AI system. This is vital since images with insufficient quality (i.e., overexposed, out-of-focus, etc.) may be deemed ungradable or be misclassified. Another signalling question added was on the conflict of interest. With the advent of AI  in healthcare, several AI software packages are currently being developed; thus, if study authors were affiliated with or funded by the software company in any way, studies may incur a high risk of bias.

 In this domain, the main quality issue was the signalling question of whether a diagnostic threshold was prespecified or not. Only three studies reported on prespecified thresholds, with the remaining 12 studies thus considered to have an unclear risk of bias. Six studies have conflicts of interest, thus deeming them high risk. All studies have low applicability concerns for the index test.

## **Reference standard**

 In the reference standard domain, three out of 15 studies were evaluated as having a high risk of bias because there were only two HGs to grade the fundus images. This may incur bias since grading images can be very subjective, and there is no one to arbitrate when a disagreement arises. Five studies have an unclear risk of bias because they did not explicitly state whether the HGs were blinded to the results of the AI grading results. All studies have low applicability concerns.

### **Flow and timing**

 In the domain of flow and timing, one study was considered to be of a high risk of bias because it was not able to explain the discrepancies in patients enrolled and analysed clearly. This domain is not assessed regarding applicability concerns, as stated in the QUADAS-2 tool.

## **Findings**

 We evaluated the accuracy of AI in screening for RDR in real-world settings according to patient-level and eye-level analysis compared with HGs. The patient-level analysis was considered the main meta- analysis since it is the number of patients with RDR who will be referred to ophthalmologists for further assessment. Out of the 15 studies reviewed, eight presented diagnostic accuracy based solely on patient-

- 272 level information, five showed diagnostic accuracy based solely on eye-level information, and two
- 273 showed diagnostic accuracy based on both patient-level and eye-level information.
- 274 The HSROC model by Rutter and Gatsonis was used for the meta-analysis as this model accounts for
- 275 the variations in the test thresholds among the AI models [31]. We performed subgroup analysis and
- 276 investigated for heterogeneity using the World Bank country classification, level of the healthcare
- 277 setting, and DR classification criteria.
- 278 We performed sensitivity analyses to explore the effect of excluding (1) studies that did not include
- 279 DME in the RDR definition and (2) studies with a total number of ≤2 HGs as the ground truth. **Table**
- 280 **2** shows the detailed overall patient-level and eye-level meta-analysis.

281

**Table 2. Overall patient-level and eye-level meta-analysis of the accuracy of AI in detecting RDR compared with trained HGs.**

Overall Meta-analysis	No of <b>Studies</b>	No of <b>Samples</b>	Sensitivity (95% CI)	Specificity (95% CI)
Patient-level	10	45 785 patients	95.33% (90.60-100)	92.01% (87.61-96.42)
Eye-level		15 390 eyes	$91.24\%$ (79.15-100)	93.90% (90.63-97.16)

Data calculated using SAS® Studio.

**CI**, Confidence Interval; **HG**, human grader.

#### 282

## 283 **Patient-level analysis**

284 Ten evaluations of AI for RDR screening were performed with data from ten studies and a total of 45

285 785 patients. The forest plot **(Fig 4)** shows minimal variation in the accuracy estimates. The HSROC

286 plot **(Fig 5)** reveals good test accuracy since most study points lie in the upper left corner of the plot.

287 Meta-analytical sensitivity and specificity of data at mixed thresholds were 95.33% (95% CI 90.60-

288 100) and 92.01% (95% CI 87.61-96.42), respectively.

- 290 **Fig 4. Coupled forest plot of included studies for patient-level analysis.**
- 291 **Fig 5. HSROC plot of sensitivity vs specificity of AI for detecting RDR on patient-level analysis.**
- 292

## **Eye-level analysis**

- A total of seven evaluations of AI for RDR screening were performed with data from seven studies and
- a total of 15 390 eyes. We only included the Aravind data from the Gulshan 2019 study because data
- from Sankara differed from our eligibility criteria.
- The forest plot **(Fig 6)** shows moderate variation in the estimates of sensitivity and minimal variation
- in specificity. The HSROC plot **(Fig 7)** reveals good test accuracy since most study points lie in the
- upper left corner of the plot. Meta-analytical sensitivity and specificity of data at mixed thresholds were

91.24% (95% CI 79.15-100) and 93.90% (95% CI 90.63-97.16), respectively.

- 
- **Fig 6. Coupled forest plot of included studies for eye-level analysis.**

**Fig 7. HSROC plot of sensitivity vs specificity of AI for detecting RDR on eye-level analysis.** 

## **Exploring heterogeneity**

 We performed subgroup analyses to explore potential sources of heterogeneity only on the main analysis (patient level), consisting of ten studies, since the data for the subgroups were more complete. A detailed result of subgroup analyses investigating potential sources of study-level heterogeneity is shown in **Table 3**.

- 
- 
- 
- 
- 
- 

<b>Analysis</b>		$\mathbf{N}$ of <b>Studies</b>	$\mathbf{N}$ of Participants	<b>Sensitivity</b> $(95\% \text{ CI})$	<b>Specificity</b> $(95\% \text{ CI})$
<b>Overall Meta-analysis</b>					
Patient-level		10	45 785	95.33% (90.60-100)	92.01% (87.61-96.42)
<b>Subgroup Analyses</b>					
World Bank Country Classification	<b>LMIC</b>	7	45 29 6	95.38% (90.38-100)	92.21% (87.19-97.23)
	<b>HIC</b>	3	489	95.61% (89.44-100)	90.82% (87.76-93.87)
Level of Health- care Setting a	Primary	$\overline{4}$	2666	99.35% (96.85-100)	93.72% (88.83-98.61)
	Tertiary	$\overline{4}$	2251	94.71% (89.00-100)	90.88% (83.22-98.53)
DR Classification Criteria	<b>ICDR</b>	8	45489	95.44% (90.70-100)	92.21% (87.80-96.62)
	NHS DES	2	296	95.49% (89.19-100)	89.85% (84.93-94.77)

**Table 3. Subgroup analyses for the accuracy of AI in detecting RDR compared with trained HGs on patient-level analysis.**

<sup>a</sup> No studies reported on secondary healthcare settings, thus not included in this table. Data calculated using SAS® Studio.

**CI**, Confidence Interval; **HG**, human grader; **HIC**, high-income country; **ICDR**, International Clinical Diabetic Retinopathy; **LMIC**, lower- and middle-income country; **NHS DES**, National Health Service Diabetic Eye Screening; **RDR**, referable diabetic retinopathy.

#### 317

#### 318 **Level of economic development**

319 We classified the level of economic development of the countries included in our study using

- 320 classification by the World Bank Group [32]. Of the ten studies included, three were conducted in HICs,
- 321 and seven were conducted in LMICs. Australia was classified as a high-income country (HIC), and
- 322 China and India, as lower- and middle-income country (LMIC). The sensitivity and specificity of AI in
- 323 the real-world screening for RDR in LMICs were 95.38% and 92.21%, respectively, and in HIC, they
- 324 were 95.61% and 90.82%, respectively **(Fig 8)**.
- 325

#### 326 **Fig 8. Coupled forest plots showing the subgroups in the level of economic development**

- 327 **according to the World Bank country classification.**
- 328 **HIC**, high-income country; **LMIC**, lower- and middle-income country
- 329
- 330

## **Level of healthcare setting**



#### 356

#### **Table 4. Sensitivity analyses for the accuracy of AI in detecting RDR compared with trained HGs on patient-level analysis.**



Data calculated using SAS® Studio.

**CI,** confidence interval**; DME,** diabetic macular edema; **HG**, human grader; **RDR,** referable diabetic retinopathy.

#### 357

#### 358 **Inclusion of DME on the RDR definition**

- 359 After excluding four studies that did not include DME as part of the RDR definition, pooled sensitivity
- 360 and specificity did not show any significant variation compared to the overall main meta-analysis

361 (95.51% vs 95.33% and 91.35% vs 92.01%, respectively) **(Fig 11)**.

362

## 363 **Fig 11. Coupled forest plot of studies that include DME on the RDR definition.**

- 364 **DME**, diabetic macular edema; **RDR**, referable diabetic retinopathy.
- 365

#### 366 **Total number of human graders**

- 367 After excluding two studies that have a total of  $\leq$  HGs as the ground truth, pooled sensitivity and
- 368 specificity also did not show any significant variation compared to the overall main meta-analysis
- 369 (94.69% vs 95.33% and 92.37% vs 92.01%, respectively) **(Fig 12)**.

- 371 **Fig 12. Coupled forest plot of studies with ≥3 human graders as the ground truth on reference**
- 372 **standard.**
- 373

## **Investigation of publication bias**

 We did not investigate publication bias since, according to Salameh, et al. [12], the statistical investigation of publication and reporting bias is not routinely recommended in systematic reviews involving DTA.

# **Discussion**

## **Summary of main findings**

 Artificial intelligence screening incorporating a range of software applications has been evaluated for detecting referable DR in real-world settings. Studies in this review came from various economic settings and level of health care, all using recognised DR classification criteria. This review provides evidence, for the first time from prospective studies, for the effectiveness of AI in screening for RDR, in real-world settings.

 This review aimed to assess the accuracy of AI solutions in detecting RDR in different resource settings. We found no variation in the diagnostic accuracy of AI, whether deployed in the LMICs or HICs, meaning AI in screening for RDR can be used universally. Regarding different DR classifications used, we found no variation between ICDR and NHS DES because both the AI models and HGs used the same criteria when grading RDR. Thus, stakeholders need to note that when integrating an AI model into a DR screening programme, the DR criteria used to train the AI model should be the same as the DR criteria used by the trained HGs in that setting or country to prevent misclassifications.

 However, on the level of the healthcare setting, studies done in the primary-level healthcare settings have higher diagnostic accuracy compared to those done in tertiary-level healthcare settings. One of the reasons may be having more patients with advanced disease or other comorbidities in tertiary care settings where screening for RDR can be more challenging.

 We applied the summary estimates to a hypothetical cohort of 1000 patients to our main analysis using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)pro guideline development tool [33] **(Table 5)**. Our findings suggest that if AI is used for the detection of RDR in



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.06.20.23291687;](https://doi.org/10.1101/2023.06.20.23291687) this version posted June 22, 2023. The copyright holder for this preprint

410

#### **Table 5. Summary of findings of the review evaluated using the GRADEpro GDT.**

**Review question:** What is the diagnostic test accuracy of AI in screening for RDR compared with trained HGs among patients with diabetes in real-world settings?

**Population:** People living with clinically diagnosed type 1 and type 2 diabetes

**Setting:** Real-world settings

**Index test:** Artificial intelligence

**Reference standard:** Trained HGs

**Study design:** Cross-sectional studies with prospective data collection

**Total № of studies:** 15 studies; **Patient-level (Main) analysis:** 10 studies (45 785 patients);



Prevalence data calculated using GRADEpro GDT.

a National prevalence estimate of RDR in India [35]

<sup>b</sup> Prevalence estimate of RDR in a multi-ethnic study involving datasets from Singapore, the USA, Hong Kong, China and Australia [34]

<sup>c</sup> **Risk of bias (-1):** QUADAS-2 tool was used to assess for the risk of bias in the 10 studies. In the domain of *Patient Selection*, the risk of bias was high in 1 study and was unclear in 8; In the domain of *Index Test*, it was high in 4 studies and unclear in 6; In the domain of *Reference Standard*, it was high in 2 studies and unclear in 4; and in the domain of *Flow and Timing*, it was high in 1 study.

<sup>d</sup> **Risk of bias (-1)**: Risk of bias was assessed in the 7 studies of this level of analysis. In the domain of *Patient Selection*, the risk of bias was high in 2 studies and was unclear in 5; In the domain of *Index Test*, it was high in 2 studies and unclear in 4; In the domain of *Reference Standard*, it was high in 2 studies and unclear in 1; and in the domain of *Flow and Timing*, it was high in 1 study.

e **Inconsistency(-1):** Statistical heterogeneity based on the forest plot showed moderate variation in the sensitivity. f **Imprecision (-1):** The CI of the pooled sensitivity is wide, indicating that there is an uncertainty in the estimate and that the true value could potentially be lower.

#### **Grade Definition** [33]

**High:** Further research is very unlikely to change our confidence in the estimate of effect; **Moderate:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate**; Low:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; **Very low:** Any estimate of effect is very uncertain.

**AI,** artificial intelligence**; CI,** Confidence Interval; **DME**, diabetic macular edema; **DR**, diabetic retinopathy; **GDT**, guideline development tool; **GRADE**, Grading of Recommendations, Assessment, Development and Evaluation; **HG**, human grader; **RDR,** referable diabetic retinopathy

 We also explored the effect of excluding studies that did not include DME in the RDR definition and found that the diagnostic accuracy of AI has no significant variation; this does not mean that inclusion or exclusion of DME is nonsignificant in screening for RDR, rather, this is because trained HGs adhered to the grading protocol of the study with regards to RDR definition. Furthermore, the effect of excluding studies with ≤2 trained HGs (ophthalmologists and trained and certified HGs from retina reading centres) did not affect the diagnostic accuracy of the data. This review, thus, highlights the importance of trained HGs acting as a reference standard for grading the fundus images.

# **Strengths and limitations of this review**

#### **Strengths**

 This is the first systematic review and meta-analysis assessing the diagnostic accuracy of AI in screening for RDR in real-world settings that included studies using prospective data collection. We did not restrict our literature search in terms of language and publication year to minimise the chance of missing studies. We were able to present the accuracy estimates in patient-level and eye-level analysis, rather than just combining these data to prevent unit-of-analysis issues and avoid bias in precision. We were able to tailor and pilot our QUADAS-2 tool to our study, adding more signalling questions to fit AI studies since QUADAS-AI by Sounderajah et al. [36] was not yet published during the time of our review. Data extraction and assessment of the risk of bias were performed by two review authors, thus, reducing the risk of bias. We avoided all case-control studies since studies involving a control group without RDR and patients with RDR may exaggerate the diagnosis accuracy [13]. We included studies using different DR criteria (rather than just restricting to certain criteria), where results showed no significant variation in the accuracy estimates.

#### **Limitations**

#### **Eligibility**

 Our definition of RDR in this review is according to how the authors of the primary studies defined them, with or without DME. In the clinical setting, cases of DME should be referred for further examination when detected. However, to accurately detect DME, optical coherence tomography (OCT), which gives detailed 3D images of the eye, is the gold standard; thus, this makes fundus images less advantageous as it only provides 2D images. Therefore, it is important that further studies be done for AI models to be trained and developed to read OCT together with fundus images for higher accuracy and better applicability.

#### **Quality of included studies**

 All eligible studies had either an unclear risk or, a high risk of bias in at least one of the QUADAS-2 domains. Amongst the included studies, 80% did not report as to how patients were enrolled in the study, making them unclear. Also, many of the studies did not clearly report a pre-specified threshold which may influence the diagnostic accuracy of the test if the authors select a positivity cut-off after obtaining the results. Thus, we support that DTA studies following the Standards for Reporting of Diagnostic Accuracy Studies (STARD) guidelines by Cohen et al. [37] or the proposed STARD-AI guidelines by Sounderajah et al. [38], when available, to avoid these uncertainties.

 Regarding the QUADAS-2 domain on flow and timing, specifically as regards the signalling question relating to whether all enrolled patients were included in the analysis, we deemed a study as high risk if the discrepancies between the enrolled and analysed patients were not motivated, or were related to the severity of RDR (even though most studies have excluded ungradable images from the analysis). This was done since including ungradable images may lead to inaccuracy and not give meaningful results. Therefore, it is important that during the implementation of AI in DR screening programmes, the protocol for evaluating images as ungradable should be available, (e.g. considering mydriasis, if needed, assuring quality images when capturing photos, etc.), to avoid missed detections and  unnecessary referrals since during DR screening, patients with fundus images deemed ungradable by AI should also be referred to ophthalmologists for proper assessment.

Another limitation found is the representativity of the level of economic development by World Bank

country classification. The subgroup for HIC is represented only by Australia, and the subgroup LMIC,

only by China and India. Although there were DTA studies conducted in other countries (i.e. USA,

Spain, Zambia, etc), they were, unfortunately, excluded against our eligibility criteria.

# **Applicability of findings to the review question**

 Concerns regarding the applicability of all included studies were deemed low, except for two studies that were not able to avoid inappropriate exclusions. We assessed the applicability of findings to our review question with low concerns since all studies included AI models that were able to detect RDR in real-world settings; included patients were all clinically diagnosed with type 1 and/or type 2 diabetes; the grading of the same images was all compared to the grading of the trained HGs.

# **Conclusion**

 Our review provides evidence that AI could effectively screen for RDR even in real-world settings. Whether in the HICs or LMICs, the detection of RDR using AI in real-world settings is highly sensitive and specific. It has higher accuracy when deployed at the primary-level than in tertiary-level healthcare settings.

## **Implications for practice**

 Although AI in screening for DR has been showing promising results, it is important to consider where to deploy them. Patient-wise, it will be able to screen more patients living with diabetes, leading to early diagnosis and treatment. It can also increase disease awareness, promoting a healthy lifestyle and diabetes control to these patients. However, healthcare-wise, AI might be unnecessarily referring a  handful of patients without RDR to tertiary healthcare centres. In HICs, where manpower is usually not an issue, this might not be a problem; however, in LMICs, where it is a challenge, referring false positive cases to the already few and straining eye health workers can overburden them. Thus, we recommend a clinical pathway in these low-resource settings, where trained or certified lay graders in primary healthcare can countercheck all the fundus images of patients who screened positive for RDR before officially referring them, rather than just leaving the referral decisions to the AI system.

# **Implications for research**

 In recent years, researchers and clinicians have been advocating the use of real-world performance of AI for healthcare to evaluate further their real impact on image quality and system usability rather than just validating them using retrospective high-quality databases [24]. Our review was able to pool the diagnostic accuracy of AI in screening RDR of studies using prospective data collection; therefore, can provide recommendations to evidence-based guidelines to integrate AI in DR screening programmes in real-world settings. We recommend further studies on integrating OCT aside from using fundus imaging in AI algorithms so screening for DME will be more accurate.

# **Acknowledgements**

 M.E.E. is supported by a grant from the South African Medical Research Council. The views and opinions expressed are those of the authors and do not necessarily represent the official views of the SA MRC.

# **Author contributions**

- **Conception of the review:** Holijah Uy, Deon Minnies, Abraham Opare
- **Development of the protocol:** Holijah Uy, Deon Minnies, Ameer Hohlfeld, Mark E Engel
- **Methodological advice:** Mark E Engel, Ameer Hohlfeld, Eleanor Ochodo

- **Content advice:** Mark E Engel, Christopher Fielding, Deon Minnies
- **Data collection:** Holijah Uy, Christopher Fielding, Elton Mukonda,
- **Data analysis:** Holijah Uy, Eleanor Ochodo, Ameer Hohlfeld, Mark E Engel
- **Writing of first draft:** Holijah Uy
- **Contributions to editing subsequent versions of the protocol and manuscript:**
- Ameer Hohlfeld, Eleanor Ochodo, Deon Minnies, Mark E Engel
- 

# **References**

- **1.** Teo ZL, Tham Y-C, Yan Yu MC, Chee ML, Rim TH, Cheung N, et al. Global prevalence of
- diabetic retinopathy and projection of burden through 2045: Systematic review and meta-
- analysis. American Academy of Ophthalmology. 2021;128.
- <https://doi.org/10.1016/j.ophtha.2021.04.027>
- **2.** Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic
- retinopathy preferred practice pattern. American Academy of Ophthalmology. 2019;127: P66–
- P145.<https://doi.org/10.1016/j.ophtha.2019.09.025>
- **3.** Cuadros J. The real-world impact of artificial intelligence on diabetic retinopathy screening in
- primary care. Journal of Diabetes Science and Technology. 2021;15: 664–665.
- <https://doi.org/10.1177/1932296820914287>
- **4.** International Council of Ophthalmology. Guidelines for diabetic eye care. San Francisco,
- California: ICO; 2017. Available:<https://icoph.org/eye-care-delivery/diabetic-eye-care/>
- **5.** Wintergerst MWM, Bejan V, Hartmann V, Schnorrenberg M, Bleckwenn M, Weckbecker K, et
- al. Telemedical diabetic retinopathy screening in a primary care setting: Quality of retinal
- photographs and accuracy of automated image analysis. Ophthalmic Epidemiology. 2021;29:
- 286–295. <https://doi.org/10.1080/09286586.2021.1939886>
- 

- **6.** Piyasena MMPN, Murthy GVS, Yip JLY, Gilbert C, Zuurmond M, Peto T, et al. Systematic
- review on barriers and enablers for access to diabetic retinopathy screening services in different
- income settings. PLoS ONE. 2019;14.<https://doi.org/10.1371/journal.pone.0198979>
- **7.** National Institute for Clinical Excellence. Clinical Guideline E: Management of Type 2
- diabetes. London: NICE; 2002.
- **8.** London School of Hygiene & Tropical Medicine. Identifying a good screening test: sensitivity,
- specificity and coverage. Future Learn. Available:

<https://www.futurelearn.com/info/courses/diabetic-eye-disease/0/steps/47640>

- **9.** Silpa-archa S, Limwattanayingyong J, Tadarati M, Amphornphruet A, Ruamviboonsuk P.
- Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region.
- Indian Journal of Ophthalmology. 2021;69: 2959–2967.
- [https://doi.org/10.4103/ijo.IJO\\_1075\\_21](https://doi.org/10.4103/ijo.IJO_1075_21)
- **10.** Raman R, Dasgupta D, Ramasamy K, George R, Mohan V, Ting D. Using artificial intelligence
- for diabetic retinopathy screening: Policy implications. Indian Journal of Ophthalmology.
- 2021;69: 2993–2998. [https://doi.org/10.4103/ijo.IJO\\_1420\\_21](https://doi.org/10.4103/ijo.IJO_1420_21)
- **11.** Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Medicine. 2019;17.
- <https://doi.org/10.1186/s12916-019-1426-2>
- **12.** Salameh J-P, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred
- reporting items for systematic review and meta-analysis of diagnostic test accuracy studies
- (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370: m2632.
- <https://doi.org/10.1136/bmj.m2632>
- **13.** Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
- A revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal
- Medicine. 2011;155: 529.<https://doi.org/10.7326/0003-4819-155-8-201110180-00009>
- 

- **14.** Cardoso JR, Pereira LM, Iversen MD, Ramos AL. What is gold standard and what is ground
- truth? Dental Press Journal of Orthodontics. 2014;19: 27–30. [https://doi.org/10.1590/2176-](https://doi.org/10.1590/2176-9451.19.5.027-030.ebo) [9451.19.5.027-030.ebo](https://doi.org/10.1590/2176-9451.19.5.027-030.ebo)
- **15.** Dong X, Du S, Zheng W, Cai C, Liu H, Zou J. Evaluation of an artificial intelligence system for
- the detection of diabetic retinopathy in Chinese community healthcare centers. Frontiers in
- Medicine. 2022;9.<https://doi.org/10.3389/fmed.2022.883462>
- **16.** Gulshan V, Rajan RP, Widner K, Wu D, Wubbels P, Rhodes T, et al. Performance of a deep-
- learning algorithm vs manual grading for detecting diabetic retinopathy in India. JAMA
- Ophthalmology. 2019;137: 987. <https://doi.org/10.1001/jamaophthalmol.2019.2004>
- **17.** Hao S, Liu C, Li N, Wu Y, Li D, Gao Q, et al. Clinical evaluation of AI-assisted screening for
- diabetic retinopathy in rural areas of Midwest China. Grzybowski A, editor. PLOS ONE.
- 2022;17: e0275983. <https://doi.org/10.1371/journal.pone.0275983>
- **18.** He J, Cao T, Xu F, Wang S, Tao H, Wu T, et al. Artificial intelligence-based screening for

diabetic retinopathy at community hospital. Eye. 2019;34: 572–576.

<https://doi.org/10.1038/s41433-019-0562-4>

- **19.** Jain A, Krishnan R, Rogye A, Natarajan S. Use of offline artificial intelligence in a smartphone-
- based fundus camera for community screening of diabetic retinopathy. Indian Journal of
- 583 Ophthalmology. 2021;69: 3150. https://doi.org/10.4103/ijo.ijo.3808\_20
- **20.** Kanagasingam Y, Xiao D, Vignarajan J, Preetham A, Tay-Kearney M-L, Mehrotra A.
- Evaluation of artificial intelligence-based grading of diabetic retinopathy in primary care.
- JAMA Network Open. 2018;1: e182665.<https://doi.org/10.1001/jamanetworkopen.2018.2665>
- **21.** Keel S, Lee PY, Scheetz J, Li Z, Kotowicz MA, MacIsaac RJ, et al. Feasibility and patient
- acceptability of a novel artificial intelligence-based screening model for diabetic retinopathy at
- endocrinology outpatient services: A pilot study. Scientific Reports. 2018;8.
- <https://doi.org/10.1038/s41598-018-22612-2>

- **22.** Li N, Ma M, Lai M, Gu L, Kang M, Wang Z, et al. A stratified analysis of a deep learning
- algorithm in the diagnosis of diabetic retinopathy in a real‐world study. Journal of Diabetes.

2021;14: 111–120. <https://doi.org/10.1111/1753-0407.13241>

- **23.** Natarajan S, Jain A, Krishnan R, Rogye A, Sivaprasad S. Diagnostic accuracy of community-
- based diabetic retinopathy screening with an offline artificial intelligence system on a
- smartphone. JAMA Ophthalmology. 2019;137: 1182.
- <https://doi.org/10.1001/jamaophthalmol.2019.2923>
- **24.** Rajalakshmi R, Subashini R, Anjana RM, Mohan V. Automated diabetic retinopathy detection
- in smartphone-based fundus photography using artificial intelligence. Eye. 2018;32: 1138–
- 1144.<https://doi.org/10.1038/s41433-018-0064-9>
- **25.** Scheetz J, Koca D, McGuinness M, Holloway E, Tan Z, Zhu Z, et al. Real-world artificial
- intelligence-based opportunistic screening for diabetic retinopathy in endocrinology and
- indigenous healthcare settings in Australia. Scientific Reports. 2021;11.
- <https://doi.org/10.1038/s41598-021-94178-5>
- **26.** Sosale B, Aravind SR, Murthy H, Narayana S, Sharma U, Gowda SGV, et al. Simple, mobile-
- based artificial intelligence algorithm in the detection of diabetic retinopathy (SMART) study.
- BMJ Open Diabetes Research & Care. 2020;8: e000892. [https://doi.org/10.1136/bmjdrc-2019-](https://doi.org/10.1136/bmjdrc-2019-000892) [000892](https://doi.org/10.1136/bmjdrc-2019-000892)
- **27.** Yang Y, Pan J, Yuan M, Lai K, Xie H, Ma L, et al. Performance of the AIDRScreening system
- in detecting diabetic retinopathy in the fundus photographs of Chinese patients: A prospective,
- multicenter, clinical study. Annals of Translational Medicine. 2022;10: 1088–1088.
- <https://doi.org/10.21037/atm-22-350>
- **28.** Zhang Y, Shi J, Peng Y, Zhao Z, Zheng Q, Wang Z, et al. Artificial intelligence-enabled
- screening for diabetic retinopathy: A real-world, multicenter and prospective study. BMJ Open
- Diabetes Research & Care. 2020;8: e001596. <https://doi.org/10.1136/bmjdrc-2020-001596>

- **29.** Zhang W, Li D, Wei Q, Ding D, Meng L, Wang Y, et al. The validation of deep learning-based
- grading model for diabetic retinopathy. Frontiers in Medicine. 2022;9.
- <https://doi.org/10.3389/fmed.2022.839088>
- **30.** Hong Kong Baptist University, Department of Mathematics. Mean variance estimation. In:
- www.math.hkbu.edu.hk [Internet]. 2023 [cited 8 Apr 2023]. Available:
- <https://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html>
- **31.** Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test
- accuracy evaluations. Statistics in Medicine. 2001;20: 2865–2884.
- <https://doi.org/10.1002/sim.942>
- **32.** Hamaddeh N, Van Rompaey C, Metreau E, Eapen SG. New World Bank country classifications
- by income level: 2022-2023. In: World Bank Blogs [Internet]. World Bank Group; 1 Jul 2022.
- Available: [https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-](https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2022-2023)[income-level-2022-2023](https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2022-2023)
- **33.** McMaster University , Evidence Prime. GRADEpro GDT: GRADEpro guideline development tool [Software]. 2022. Available: gradepro.org
- **34.** Ting DSW, Cheung CY, Nguyen Q, Sabanayagam C, Lim G, Lim ZW, et al. Deep learning in
- estimating prevalence and systemic risk factors for diabetic retinopathy: A multi-ethnic study.
- Nature Partner Journals: Digital Medicine. 2019;2.<https://doi.org/10.1038/s41746-019-0097-x>
- **35.** Sheikh A, Bhatti A, Adeyemi O, Raja M, Sheikh I. The utility of smartphone-based artificial
- intelligence approaches for diabetic retinopathy: A literature review and meta-analysis. Journal
- of Current Ophthalmology. 2021;33: 219. <https://doi.org/10.4103/2452-2325.329064>
- **36.** Sounderajah V, Ashrafian H, Rose S, Shah NH, Ghassemi M, Golub R, et al. A quality
- assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-
- AI. Nature Medicine. 2021;27: 1663–1665. <https://doi.org/10.1038/s41591-021-01517-0>
- 
- **37.** Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015
- guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open.
- 2016;6: e012799. <https://doi.org/10.1136/bmjopen-2016-012799>

- **38.** Sounderajah V, Ashrafian H, Golub RM, Shetty S, De Fauw J, Hooft L, et al. Developing a
- reporting guideline for artificial intelligence-centred diagnostic test accuracy studies: the
- STARD-AI protocol. BMJ Open. 2021;11: e047709. [https://doi.org/10.1136/bmjopen-2020-](https://doi.org/10.1136/bmjopen-2020-047709)

[047709](https://doi.org/10.1136/bmjopen-2020-047709)

# **Supporting Information**

- **S1 Table. Search strategy**
- **S2 Table. PRISMA-DTA**

















# **LMIC**



# **HIC**





# **Primary Level**





## **Tertiary Level**





# **ICDR**



# **DME** Included





# Human Graders  $\geq 3$

